Short Interest in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Rises By 23.0%

Key Points

• Short interest rose by 23.0% in April to 2,834,997 shares, equal to about 5.8% of the company's stock and a days-to-cover ratio of 4.1 days.
• Shares traded at $1.34 with a market cap of $81.3 million; MAIA reported Q1 EPS of ($0.08) (beating estimates of ($0.13)) while analysts forecast a full‑year EPS of -0.69.
• Institutional ownership is low at 5.65%, though several firms recently established or increased positions (notably Geode with 222,183 shares and Centric Wealth with 586,398 shares).

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - Get Free Report) saw a large increase in short interest during the month of April. As of April 15th, there was short interest totaling 2,834,997 shares, an increase of 23.0% from the March 31st total of 2,304,530 shares. Approximately 5.8% of the company's stock are short sold. Based on an average daily trading volume, of 698,485 shares, the days-to-cover ratio is currently 4.1 days.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of MAIA. Marshall Wace LLP acquired a new position in shares of MAIA Biotechnology in the 2nd quarter worth approximately $29,000. Ritholtz Wealth Management acquired a new stake in shares of MAIA Biotechnology during the 4th quarter valued at approximately $35,000. Jane Street Group LLC bought a new position in MAIA Biotechnology during the second quarter worth $52,000. Geode Capital Management LLC lifted its stake in MAIA Biotechnology by 3.6% during the second quarter. Geode Capital Management LLC now owns 222,183 shares of the company's stock worth $400,000 after purchasing an additional 7,746 shares during the last quarter. Finally, Centric Wealth Management boosted its holdings in MAIA Biotechnology by 2.0% in the fourth quarter. Centric Wealth Management now owns 586,398 shares of the company's stock worth $897,000 after purchasing an additional 11,500 shares during the period. Institutional investors own 5.65% of the company's stock.

MAIA Biotechnology Price Performance

Shares of NYSEAMERICAN:MAIA traded up $0.01 during midday trading on Friday, reaching $1.34. The company had a trading volume of 580,779 shares, compared to its average volume of 661,763. The stock has a market capitalization of $81.30 million, a P/E ratio of -1.94 and a beta of 0.21. The stock's fifty day moving average price is $1.51 and its 200-day moving average price is $1.52. MAIA Biotechnology has a one year low of $0.87 and a one year high of $3.19.

MAIA Biotechnology (NYSEAMERICAN:MAIA - Get Free Report) last posted its quarterly earnings data on Monday, March 23rd. The company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.05. As a group, sell-side analysts forecast that MAIA Biotechnology will post -0.69 earnings per share for the current year.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company's pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.